全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Lower Extremity Ulcers in Patients with Systemic Sclerosis

DOI: 10.4236/ojra.2022.121005, PP. 35-45

Keywords: Lower Extremity Ulcers, Systemic Sclerosis, Scleroderma, Peripheral Vascular Disease, Venous Stasis

Full-Text   Cite this paper   Add to My Lib

Abstract:

Introduction: Cutaneous manifestations of systemic sclerosis (SSc) include skin ulceration; 4% - 12% of patients with SSc develop lower extremity ulcers of various etiologies. Limited data, significant morbidity, and substantial cost of wound care led us to undertake this study to describe and identify risk factors. Methods: After Institutional Review Board approval, we identified 30 patients with SSc and lower extremity ulcers over a 10-year period at a single center with an SSc clinic, which were included in a descriptive analysis. Results: Median age of onset of lower extremity ulcers was 59.5 years (range 20 - 84). Ninety percent of patients were female, 60% were Caucasian, 63% had limited SSc, 13% diffuse SSc and 23% an overlap syndrome. Immunomodulators or steroids were prescribed in 53%; hypercoagulable state identified in 16%. Ulcers were attributed to venous stasis (27%), SSc (20%), trauma (20%), arterial disease (17%), and multifactorial/unknown (17%). In patients with ulcers attributed to SSc, age at onset was lower (45.5 vs 59.5 years). Biopsies generally did not contribute to management. Multidisciplinary treatment was routine; 20% required amputation, 10% endovascular intervention, 20% frequent surgical debridement, 10% hyperbaric oxygen, 26% local treatment and antibiotics and 13% received immunosuppression for wound treatment. Conclusion: Lower extremity ulcers are a serious clinical problem in patients with SSc. The clinical exam, venous dopplers, ankle-brachial indices and assessment of vascular risk factors helped define causality. In younger patients, ulcers were more frequently attributed to SSc and these patients were more likely to be on immunosuppressants/DMARDS, possibly indicating severe phenotype of SSc.

References

[1]  Gabrielli, A., Avvedimento, E.V. and Krieg, T. (2009) Scleroderma. The New England Journal of Medicine, 360, 1989-2003.
https://doi.org/10.1056/NEJMra0806188
[2]  Strange, G. and Nash, P. (2009) The Manifestations of Vasculopathy in Systemic Sclerosis and Its Evidence-Based Therapy. International Journal of Rheumatic Diseases, 12, 192-206.
https://doi.org/10.1111/j.1756-185X.2009.01410.x
[3]  Shanmugam, V.K., Price, P., Attinger, C.E. and Steen, V.D. (2010) Lower Extremity ULCERS in Systemic Sclerosis: Features and Response to Therapy. International Journal of Rheumatology, 2010, Article ID: 747946.
https://doi.org/10.1155/2010/747946
[4]  Bohelay, G., Blaise, S., Levy, P., et al. (2018) Lower-Limb Ulcers in Systemic Sclerosis: A Multicentre Retrospective Case-control Study. Acta Dermato-Venereologica, 98, 677-682.
https://doi.org/10.2340/00015555-2939
[5]  Blagojevic, J., Piemonte, G., Benelli, L., et al. (2016) Assessment, Definition, and Classification of Lower Limb Ulcers in Systemic Sclerosis: A Challenge for the Rheumatologist. The Journal of Rheumatology, 43, 592-598.
https://doi.org/10.3899/jrheum.150035
[6]  Taniguchi, T., Asano, Y., Hatano, M., et al. (2012) Effects of Bosentan on Nondigital Ulcers in Patients with Systemic Sclerosis. British Journal of Dermatology, 166, 417-421.
https://doi.org/10.1111/j.1365-2133.2011.10581.x
[7]  Nussbaum, S.R., Carter, M.J., Fife, C.E., et al. (2018) An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. Value Health, 21, 27-32.
https://doi.org/10.1016/j.jval.2017.07.007
[8]  Merkel, P.A., Chang, Y., Pierangeli, S.S., Convery, K., Harris, E.N. and Polisson, R.P. (1996) The Prevalence and Clinical Associations of Anticardiolipin Antibodies in a Large Inception Cohort of Patients with Connective Tissue Diseases. The American Journal of Medicine, 101, 576-583.
https://doi.org/10.1016/S0002-9343(96)00335-X
[9]  Schoenroth, L., Fritzler, M., Lonzetti, L. and Senécal, J.-L. (2002) Antibodies to Beta2 Glycoprotein I and Cardiolipin in SSc. Annals of the Rheumatic Diseases, 61, 183-184.
https://doi.org/10.1136/ard.61.2.183-a

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133